Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NVAX – Novavax, Inc.

Novavax, Inc.
NVAX
$7.42
Name : Novavax, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,201,007,488.00
EPSttm : 2.75
finviz dynamic chart for NVAX
Novavax, Inc.
$7.42
6.08%
$0.425

Float Short %

31.48

Margin Of Safety %

Put/Call OI Ratio

0.68

EPS Next Q Diff

-3.17

EPS Last/This Y

3.79

EPS This/Next Y

-2.24

Price

6.99

Target Price

15.29

Analyst Recom

2.14

Performance Q

-11.18

Relative Volume

0.66

Beta

2.77

Ticker: NVAX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07NVAX5.940.850.51283413
2025-05-08NVAX6.640.840.14286992
2025-05-09NVAX5.970.740.33311746
2025-05-12NVAX6.340.740.19301219
2025-05-13NVAX6.180.720.21306529
2025-05-14NVAX5.950.720.19309050
2025-05-15NVAX6.30.710.07313794
2025-05-16NVAX6.730.710.30314166
2025-05-19NVAX7.730.680.37288341
2025-05-20NVAX7.680.670.43362471
2025-05-21NVAX7.120.680.31382865
2025-05-22NVAX7.260.660.15389833
2025-05-23NVAX7.250.630.07405220
2025-05-27NVAX7.380.660.15368234
2025-05-28NVAX6.930.650.38373700
2025-05-29NVAX7.180.650.22382690
2025-05-30NVAX7.330.640.16386925
2025-06-02NVAX7.050.680.40360666
2025-06-03NVAX7.260.680.13367257
2025-06-04NVAX7.140.680.16369488
2025-06-05NVAX6.990.680.32374412
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07NVAX5.95234.0- 0.49
2025-05-08NVAX6.65234.0- 0.49
2025-05-09NVAX5.97-102.0- 0.45
2025-05-12NVAX6.34-102.0- 0.45
2025-05-13NVAX6.19-84.8- 0.45
2025-05-14NVAX5.95-110.1- 0.45
2025-05-15NVAX6.30-110.1- 0.45
2025-05-16NVAX6.73-110.1- 2.40
2025-05-19NVAX7.74-110.1- 2.40
2025-05-20NVAX7.68-110.1- 2.40
2025-05-21NVAX7.12-124.2- 2.40
2025-05-22NVAX7.29-124.2- 2.40
2025-05-23NVAX7.25-124.2- 2.40
2025-05-27NVAX7.38-124.2- 2.56
2025-05-28NVAX6.92-124.2- 2.56
2025-05-29NVAX7.18-124.2- 2.56
2025-05-30NVAX7.34-124.2- 2.56
2025-06-02NVAX7.07-124.2- 2.56
2025-06-03NVAX7.26-124.2- 2.56
2025-06-04NVAX7.14-124.2- 2.56
2025-06-05NVAX6.99-124.2- 2.56
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07NVAX-0.101.1327.80
2025-05-08NVAX-0.101.1327.80
2025-05-09NVAX-0.101.1327.80
2025-05-12NVAX-0.10-0.6528.68
2025-05-13NVAX-0.10-0.6528.68
2025-05-14NVAX-0.10-0.6528.68
2025-05-15NVAX-0.10-0.6528.68
2025-05-16NVAX-0.10-0.6528.68
2025-05-19NVAX-0.10-1.5128.68
2025-05-20NVAX-0.10-1.5128.68
2025-05-21NVAX-0.10-1.5128.68
2025-05-22NVAX-0.10-1.5128.68
2025-05-23NVAX-0.10-1.5128.68
2025-05-27NVAX-0.10-5.3728.68
2025-05-28NVAX-0.10-5.3731.48
2025-05-29NVAX-0.10-5.3731.48
2025-05-30NVAX-0.10-5.3731.48
2025-06-02NVAX-0.10-4.8731.48
2025-06-03NVAX-0.10-4.8731.48
2025-06-04NVAX-0.10-4.8731.48
2025-06-05NVAX-0.10-4.8731.48
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

2.93

Avg. EPS Est. Current Quarter

-0.05

Avg. EPS Est. Next Quarter

-0.24

Insider Transactions

-0.1

Institutional Transactions

-4.87

Beta

2.77

Average Sales Estimate Current Quarter

134

Average Sales Estimate Next Quarter

118

Fair Value

Quality Score

96

Growth Score

35

Sentiment Score

37

Actual DrawDown %

97.9

Max Drawdown 5-Year %

-98.8

Target Price

15.29

P/E

2.64

Forward P/E

19.62

PEG

0.04

P/S

0.9

P/B

P/Free Cash Flow

EPS

2.65

Average EPS Est. Cur. Y​

2.56

EPS Next Y. (Est.)

0.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

38.14

Relative Volume

0.66

Return on Equity vs Sector %

-656.8

Return on Equity vs Industry %

-639

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

2.06

EBIT Estimation

Novavax, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 952
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
stock quote shares NVAX – Novavax, Inc. Stock Price stock today
news today NVAX – Novavax, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NVAX – Novavax, Inc. yahoo finance google finance
stock history NVAX – Novavax, Inc. invest stock market
stock prices NVAX premarket after hours
ticker NVAX fair value insiders trading